Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 141

Related Articles by Review for PubMed (Select 18489987)

1.

High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells.

Young FM, Campbell A, Emo KL, Jansson J, Wang PY, Jordan CT, Mullen CA.

Biol Blood Marrow Transplant. 2008 Jun;14(6):622-30. doi: 10.1016/j.bbmt.2008.02.015. Epub 2008 Apr 14.

2.

The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias.

Williams RT, Sherr CJ.

Cold Spring Harb Symp Quant Biol. 2008;73:461-7. doi: 10.1101/sqb.2008.73.039. Epub 2008 Nov 21. Review.

PMID:
19028987
3.
4.

[Target antigens for graft-versus-host disease (GVHD) and graft-versus-leukemia/tumor (GVL/T)].

Tanaka J.

Nihon Rinsho. 2003 Sep;61(9):1512-9. Review. Japanese.

PMID:
14515717
5.

The evolving role of bone marrow transplantation in the treatment of chronic myelogenous leukemia.

Delage R, Ritz J, Anderson KC.

Hematol Oncol Clin North Am. 1990 Apr;4(2):369-88. Review.

PMID:
2182597
6.

Minor histocompatibility antigens--targets of graft versus leukemia responses.

Riddell SR, Murata M, Bryant S, Warren EH.

Int J Hematol. 2002 Aug;76 Suppl 2:155-61. Review.

PMID:
12430918
7.

Biology and treatment of chronic myeloid leukemia.

Jones RJ.

Curr Opin Oncol. 1997 Jan;9(1):3-7. Review.

PMID:
9090488
8.

Graft-versus-leukemia reactions in allogeneic chimeras.

Kolb HJ, Schmid C, Barrett AJ, Schendel DJ.

Blood. 2004 Feb 1;103(3):767-76. Epub 2003 Sep 4. Review.

9.

Chronic myeloid leukemia as an immunological target.

Lim SH, Coleman S.

Am J Hematol. 1997 Jan;54(1):61-7. Review.

PMID:
8980262
10.

Disease progression in a murine model of bcr/abl leukemogenesis.

van Etten RA.

Leuk Lymphoma. 1993;11 Suppl 1:239-42. Review.

PMID:
8251903
11.

T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl.

Cheever MA, Chen W, Disis ML, Takahashi M, Peace DJ.

Ann N Y Acad Sci. 1993 Aug 12;690:101-12. Review.

PMID:
8103658
12.

Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.

Deremer DL, Ustun C, Natarajan K.

Clin Ther. 2008 Nov;30(11):1956-75. doi: 10.1016/j.clinthera.2008.11.014. Review.

PMID:
19108785
13.

Modeling Philadelphia chromosome positive leukemias.

Wong S, Witte ON.

Oncogene. 2001 Sep 10;20(40):5644-59. Review.

14.
15.

Models of chronic myeloid leukemia.

Van Etten RA.

Curr Oncol Rep. 2001 May;3(3):228-37. Review.

PMID:
11296133
16.

T cell-mediated graft-versus-leukemia reactions after allogeneic stem cell transplantation.

Schetelig J, Kiani A, Schmitz M, Ehninger G, Bornhäuser M.

Cancer Immunol Immunother. 2005 Nov;54(11):1043-58. Epub 2005 May 11. Review.

PMID:
15887014
17.

Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation.

Blair A, Goulden NJ, Libri NA, Oakhill A, Pamphilon DH.

Blood Rev. 2005 Nov;19(6):289-300. Epub 2005 Apr 7. Review.

PMID:
16275419
18.

The biology of chronic myelogenous leukemia:mouse models and cell adhesion.

Wertheim JA, Miller JP, Xu L, He Y, Pear WS.

Oncogene. 2002 Dec 9;21(56):8612-28. Review.

19.

Minor histocompatibility antigens as targets of graft-versus-leukemia reactions.

Falkenburg JH, Marijt WA, Heemskerk MH, Willemze R.

Curr Opin Hematol. 2002 Nov;9(6):497-502. Review.

PMID:
12394171
20.

The role of FAS-mediated apoptosis in chronic myelogenous leukemia.

Selleri C, Maciejewski JP.

Leuk Lymphoma. 2000 Apr;37(3-4):283-97. Review.

PMID:
10752980
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk